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The reliable derivation of induced pluripotent stem cells (iPSCs) from a noninvasive autologous source at birth
would facilitate the study of patient-specific in vitro modeling of congenital diseases and would enhance
ongoing efforts aimed at developing novel cell-based treatments for a wide array of fetal and pediatric dis-
orders. Accordingly, we have successfully generated iPSCs from human fetal chorionic somatic cells extracted
from term pregnancies by ectopic expression of OCT4, SOX2, KLF4, and cMYC. The isolated parental somatic
cells exhibited an immunophenotypic profile consistent with that of chorionic mesenchymal stromal cells
(CMSCs). CMSC-iPSCs maintained pluripotency in feeder-free systems for more than 15 passages based on
morphology, immunocytochemistry, and gene expression studies and were capable of embryoid body formation
with spontaneous trilineage differentiation. CMSC-iPSCs could be selectively differentiated in vitro into var-
ious germ layer derivatives, including neural stem cells, beating cardiomyocytes, and definitive endoderm. This
study demonstrates the feasibility of term placental chorion as a novel noninvasive alternative to dermal
fibroblasts and cord blood for human perinatal iPSC derivation and may provide additional insights regarding
the reprogramming capabilities of extra-embryonic tissues as they relate to developmental ontogeny and
perinatal tissue engineering applications.
Introduction
The seminal work by Yamanaka and colleagues,among others, on reprogramming somatic cells into a
pluripotent state has reinvigorated the field of stem cell bi-
ology.1,2 Pluripotency and the indefinite capacity for self-
renewal similar to embryonic stem cells (ESCs) can be
achieved with mouse embryonic fibroblasts (MEFs) as well
as human dermal fibroblasts by forced expression of four
transcription factors: OCT4, SOX2, KLF4, and cMYC
(OSKM). Patient-specific induced pluripotent stem cell
(iPSC) technologies can provide a useful model to study
disease pathogenesis of specific tissues, particularly for
disorders in which no suitable in vitro or animal model
currently exists.3 Moreover, the generation of iPSCs has
provided new opportunities for the development of fetal
cell-based therapies, an area within regenerative medicine
that has been hampered by a general lack of reliable and
ethically acceptable alternative to human ESCs for trans-
plantation purposes.
Since these initial reports, other somatic cells obtained
from tissues, including liver, fat, and blood, have been re-
programmed into iPSCs using defined factors.4,5 The pla-
centa, an extra-embryonic organ that is traditionally
discarded at birth, has only recently been explored for its
pluripotency and iPSC reprogramming capabilities.6–8 Since
the chorionic layer represents the predominant mass fraction
of the placental membrane,6,9 we sought to generate new
iPSC lines derived from term human placental chorionic
mesenchymal stromal cells (CMSCs) and to explore their
therapeutic potential by controlled and selective differenti-
ation into various germ layer derivatives in vitro.
Materials and Methods
Isolation of placental CMSCs
The ethical approval was given by the Institutional Re-
view Board and the Human Pluripotent Stem Cell Research
Oversight Committee at the University of Michigan (No.
38565). After written informed consent, human placentae
(n= 9) were retrieved fresh from healthy uncomplicated
pregnancies following elective cesarean section at the Von
Voigtlander Women’s Hospital, University of Michigan
Health System. The chorion was mechanically separated
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from the amnion and chorionic villi and decidua. Specimens
were washed and enzymatically digested in collagenase
(1.25mg/mL; Worthington Biochemical) and dispase
(1.2U/mL; Worthington Biochemical) for 1–2 h at 37C
with agitation. Cells were washed twice before resuspension
in mesenchymal basal medium (DMEM, 10% fetal bovine
serum, 100U/mL penicillin and 100mg/mL streptomycin,
and 2mM l-glutamine; Sigma-Aldrich).
Characterization of CMSCs
CMSCs between passages 3 and 5 were evaluated for MSC
characteristics based on criteria as described elsewhere.10 For
flow cytometry, the primary antibodies used were phycoery-
thron-conjugated against CD34, CD44, CD45, CD73, CD90,
CD105, OCT4A, SOX2, SSEA3, SSEA4, TRA-1-60, TRA-1-
81, and HLA-DR (all from BD Biosciences). Evaluation of
antibody staining was performed using the LSRII flow cyt-
ometer (BD Biosciences), and the resultant data were analyzed
using FloJo software (Tree Star). To evaluate the proliferation
and clonogenic capacity of CMSCs in culture, colony-forming
unit-fibroblast (CFU-F) assays were performed in triplicate as
previously described.11 Adipocyte and osteoblast differentia-
tion of CMSCs was performed using established protocols.12
iPSC derivation and analysis
iPSC derivation was performed by ectopic Yamanaka factor
reprogramming techniques as described elsewhere.11,13 Briefly,
293FT cells (Invitrogen) were transfected by the calcium
phosphate precipitation method with pUMVC and pCMV-
VSV-g plasmids, in addition to pMX-hKLF4, -hSOX2,
-hOCT4, -hcMYC, and -RFP plasmids, at a 1:1:1 ratio. The
supernatant was used to transduce three randomly selected
CMSC samples (CMSC-1, CMSC-2, and CMSC-3) at passage
4 at a multiplicity of infection of 5. At day 6, the cells were
split and placed on irradiated MEFs feeder layers. All cells,
including H9-ESCs controls, were cultured in human ES
conditioned medium (GlobalStem) with 4 ng/mL of FGF-2
(Millipore). Individual colonies derived from CMSCs were
subsequently picked and propagated on MEFs, Matrigel (BD
Biosciences), or PMEDSAH, a novel and defined synthetic
matrix polymer.11 Alkaline phosphatase staining was per-
formed using the AP substrate kit (Vector Laboratories) ac-
cording to the manufacturer’s instructions. Embryoid bodies
(EBs) were formed in suspension culture and analyzed based
on the methods described previously.14
Total RNA was reverse transcribed into cDNA before am-
plification with the appropriate positive and negative controls
in triplicate to 35 cycles (Life Technologies). The primer se-
quences for reverse transcription polymerase chain reaction
(RT-PCR) are shown in Supplementary Table S1 (Supple-
mentary Data are available online at www.liebertpub.com/tec).
Relative gene expression was analyzed by quantitative poly-
merase chain reaction (qPCR), with GAPDH used as a refer-
ence gene for the normalization of target gene expression using
the 2-DDCt method.15 The primer sequences used for qPCR are
shown in Supplementary Table S2.
To assay pluripotency, primary antibodies against
NANOG (Abcam), OCT4 (Santa Cruz), SOX2, SSEA3,
SSEA4, TRA-1-60, and TRA-1-81 (Millipore) were used.
Primary antibodies used to evaluate the differentiation were
against Nestin (Millipore), Neuron-specific class beta III
tubulin (TuJ1; Covance), PSA-NCAM (Millipore), a-actinin
(Sigma-Aldrich), Myosin heavy chain (MF20 and MYH7),
MLC2v (Proteintech), a-smooth muscle actin (a-SMA),
alpha fetoprotein (AFP), FOXA2, and SOX17 (R&D Sys-
tems). Cells were examined by epifluorescence microscopy
(Leica). Karyotyping was performed on CMSC-iPSC lines
every five passages by Cell Line Genetics, Inc.
Neural differentiation
Neural differentiation of iPSCs was conducted based on
modifications of a protocol described elsewhere.16 Briefly,
CMSC-iPSC colonies at passage 7 were manually cut and
transferred into 60-mm Petri dishes for 4 days followed by
culture in the neuron induction medium (DMEM/F12,
GlutaMAX, NEAA, and N2; Invitrogen) for 2 days. The
resulting neurospheres were transferred into polyornithine/
laminin-coated six-well plates (Sigma-Aldrich) to facilitate
rosette formation. Individual rosettes were manually iso-
lated, dissected, and replated into dishes containing neural
stem cell (NSC) media (Neurobasal media, B27 [Invitro-
gen], NEAA, GlutaMAX, and FGF-2).
Cardiac differentiation
Cardiomyocyte differentiation of iPSCs was performed us-
ing the Matrigel sandwich technique as previously detailed.17
Briefly, CMSC-iPSC clones at passage 14 were incubated with
TrypleE (Invitrogen) at 37C for 5min to obtain a single-cell
suspension. The cells were seeded into Matrigel-coated 12-
well plates at a density of 100,000 cells/cm2 in mTESR1
medium (StemCell Technologies) and grown to near conflu-
ence, at which time the wells were overlaid with additional
Matrigel. Once the cells were 100% confluent, the media was
replaced with RPMI 1640 (Invitrogen) containing B27 and
100ng/mL activin A (R&D Systems). After 24 h, the media
was supplemented with 10ng/mL BMP4 (R&D Systems) and
FGF-2 for another 4 days.
Definitive endodermal differentiation
Directed differentiation of iPSCs toward a definitive en-
dodermal (DE) phenotype was performed based on pub-
lished methods.18,19 Briefly, CMSC-iPSC colonies between
passages 11 and 14 were exposed to dispase, triturated, and
plated in Matrigel-coated 24-well plates. When 85–90%
confluent, the cells were cultured in endodermal differenti-
ation media containing RPMI 1640, 100 ng/mL activin A,
and 0–2% fetal bovine serum for 3 days and analyzed by
immunofluorescence staining and gene expression as de-
scribed previously.
Statistical analyses
Quantitative data were performed in triplicate and presented
as themean–SEM.Thedatawere analyzedbyone-wayanalysis
of variancewith Bonferroni correction formultiple comparisons
using GraphPad Prism software (version 5.0d). Results were
considered to be statistically significant if p£ 0.05.
Results
Plastic adherent fibroblast-appearing cells were detected
from all specimens (mean gestational age, 37 weeks) within
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1 week after seeding. The cells grew in monolayers and
displayed a relatively homogeneous spindle-shaped mor-
phology after the first passage (Fig. 1A, upper left). In seven
of nine (78%) samples, cell lines were successfully cultured
for up to six passages at a ratio of 1:4 without evidence of
reduced cell proliferation. Lack of maternal contamination
among CMSCs from male neonates was confirmed by SRY
and X-linked amelogenin gene expression (Supplementary
Fig. S1).
Chorionic cells were clonogenic, demonstrating a CFU-F of
5.70– 1.43 colonies for every 100 cells plated (Fig. 1A, lower
left). The mean number of placental chorion-derived cells
obtained from a 1 cm2 biopsy was 1.1·108 cells (range,
8.0·106–6.4·108 cells) after 26.1–3.1 days in culture.
CMSCs were able to differentiate into various mesoder-
mal cells types, namely adipocytes and osteocytes, when
cultured in the appropriate directive media for 3 weeks (Fig.
1A, B). Evidence of adipogenic differentiation was indi-
cated by the presence of Oil Red O-positive lipid vacuoles
within the cytoplasm of a subpopulation of CMSCs (Fig.
1A, upper right) and by increased expression of adipocyte-
specific genes, including fatty acid binding protein-4
(FABP4, Fig. 1B, upper) and peroxisome proliferator-
activated receptor gamma (PPARg, data not shown),
compared to CMSCs in the control medium. Osteogenic
differentiation was less robust but was positive as shown
by increased extracellular calcium matrix staining in the
presence of Alizarin Red (Fig. 1A, lower right) and by
FIG. 1. Characterization of human chorionic mesenchymal stromal cells (CMSCs). (A) Phase-contrast photomicrograph
illustrating typical CMSC morphology at passage 4 (upper left, magnification, 100· ). Representative colony-forming unit-
fibroblast (CFU-F) from CMSCs in serial dilution assays (lower left, magnification, 60· ). Oil Red O staining of CMSC-2 under
adipogenic conditions for 21 days reveals orange-red cytoplasmic lipid droplets consistent with adipocytes (upper right, mag-
nification, 100· ). Alizarin Red S staining of CMSC-2 in osteogenic conditions for 21 days shows early extracellular mineral
deposition (lower right, magnification, 100· ). (B) Representative quantitative polymerase chain reaction (qPCR) demonstrates
the upregulation of the adipogenic marker, fatty acid binding protein 4, (FABP4, upper), and the osteogenic marker, osteocalcin
(OC, lower) in CMSC-2 under adipogenic and osteogenic conditions, respectively (*denotes p£ 0.05). (C) Immunophenotypic
characterization of CMSC-1 (shown in red compared with blue negative control) at passage 4 in mesenchymal basal media,
confirming a mesenchymal stromal cell profile with positive staining for CD44, CD73, CD90, and CD105 (upper), and negative
staining for CD34, CD45, HLR-DR, and SSEA3 (lower). Color images available online at www.liebertpub.com/tec
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expression of the late osteogenic-specific gene, osteocalcin
(OC), compared to CMSCs in the control medium (Fig. 1B,
lower).
Flow cytometry revealed that the immunophenotypic
profile of culture-expanded CMSCs was consistent with that
of MSCs derived from bone marrow and other postnatal
sources (Fig. 1C). CMSCs highly expressed several mes-
enchymal surface epitope markers, including CD44 (99.2%
of cells), CD73 (98.7%), CD90 (99.0%), and CD105
(93.2%). In contrast, less than 1% of cells expressed HLA-
DR and hematopoietic stem cell markers, including CD34,
CD45, and CD117. One percent of CMSCs expressed
OCT4A, whereas 6.5% and 34.4% of cells displayed SSEA3
and SSEA4, respectively (data not shown).
The transfection efficiency of the reprogramming vectors
based on RFP expression was 61.3%– 25.3% (Fig. 2A).
After an initial period characterized by increased cell death,
surviving CMSCs began to aggregate while reducing in size
and losing their spindle-shaped morphology between 14 and
21 days in culture. At 28 days, candidate iPSC colonies
derived from all three CMSC lines showed well-defined
borders and high nuclear-to-cytoplasm ratios making them
indistinguishable from undifferentiated H9-ESCs. The re-
programming efficiency of CMSCs into iPSC-like colonies
was 0.01% – 0.005%.
Mature candidate iPSC cell lines derived from repro-
grammed CMSCs (herein referred to as CMSC-iPSCs) were
successfully transferred onto feeder-free systems, including
either Matrigel- or PMEDSAH-coated dishes, for further
expansion, subculture, and characterization (Fig. 2B). We
confirmed that CMSC-iPSCs expressed high levels of al-
kaline phosphatase and NANOG (Fig. 2B). Similar to H9-
ESC, immunofluorescence staining showed uniformly high
expression of OCT4, SOX2, SSEA3, SSEA4, TRA-1-60,
and TRA-1-81 within CMSC-iPSC colonies (Fig. 2C). In the
absence of reprogramming, CMSCs did not display any of
these pluripotency markers (data not shown).
Qualitative gene expression analyses of multiple CMSC-
iPSC lines demonstrated marked upregulation of NANOG
as well as increased expression of SOX2 (Fig. 3A). The
expression of TERT, KLF4, and cMYC was also increased
in CMSC-iPSCs compared to CMSCs (data not shown).
Although the expression of NANOG by RT-PCR was uni-
formly very low among CMSCs, endogenous expression of
SOX2 and OCT4 at baseline was often evident (Fig. 3A).
Loss of a-SMA expression normally present in CMSCs was
seen following conversion to iPSCs.
There was an *1000-fold upregulation in NANOG in
CMSC-iPSCs compared to CMSCs by qPCR (Fig. 3B). There
was similar upregulation in OCT4 and SOX2 in CMSCs-
iPSCs comparable to the levels observed in H9-ESCs. We
also observed strong transcription of TERT in CMSC-iPSCs
compared to undetectable TERT levels in CMSC controls.
Established CMSC-iPSC lines from all three patients
were maintained beyond 15 passages without morphological
change. Furthermore, they could be cryopreserved in 10%
FIG. 2. Characterization of human induced pluripotent stem cells (iPSCs) derived from CMSCs. (A) Phase-contrast
photomicrograph of CMSC-1 (upper, 40· ) following retroviral infection with Yamanaka factors and RFP reporter plasmid
on day 2 (lower, magnification, 40· ). (B) Representative colony morphology of CMSC-iPSCs grown on mouse embryonic
feeders (upper left, Feeder) and Matrigel (upper middle) under brightfield microscopy (magnification, 100· ). Early colony
with evidence of pluripotency by alkaline phosphatase (AP) staining (upper right, magnification, 20 · ). Superimposition of
DAPI and anti-NANOG immunocytochemistry (lower right). (C) Photomicrographs of reprogrammed human CMSC-1
(upper) and H9-ESC controls (lower) on mouse feeder layers, demonstrating expression of the following pluripotency
markers: NANOG, OCT4, SOX2, SSEA4, TRA-1-60, and TRA-1-81 (magnification, 20· ). DAPI staining in blue. ESC,
embryonic stem cell. Color images available online at www.liebertpub.com/tec
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DMSO and subsequently thawed with excellent survival and
re-expansion capabilities. Cytogenetic analyses revealed a
normal karyotype, indicating that these iPSCs remained free
of nonclonal aberrations after continuous expansion in cul-
ture (Fig. 3C).
In an effort to determine if CMSC-iPSCs were pluripotent
in vitro, cells between passages 7 and 9 were allowed to
differentiate into EBs. Whereas CMSCs did not form EBs or
survive in suspension culture, CMSC-iPSCs were capable of
robust EB formation after 7 days in suspension culture
(Fig. 4A). Between 21 and 28 days, RT-PCR analyses of EBs
derived from CMSC-iPSCs showed successful differentiation
into endodermal cells by AFP and GATA4 expression, into
mesodermal cells by a-SMA and DCN expression, and into
ectodermal cells by SOX1 and TuJ1 expression (Fig. 4B).
With the exception of TuJ1, these genes were expressed at
low levels in parental CMSCs. Immunocytochemistry anal-
ysis of EBs showed the presence of all three germ layer
derivatives (Fig. 4C). Cells at the periphery of the EBs had a
flattened morphology that were positive for endoderm
FIG. 3. Genetic analysis of human iPSCs derived from CMSCs. (A) Reverse transcription polymerase chain reaction
(RT-PCR) of RNAs from iPSCs showing upregulation of NANOG and downregulation of a-SMA. (B) Quantitative analysis
by qPCR demonstrating marked upregulation of pluripotency genes, including NANOG, OCT4, SOX2, and TERT, among
CMSC-iPSCs (n = 3) to levels comparable to that of H9-ESCs. Data were normalized relative to dermal fibroblast controls
and presented as the mean – SEM (n = 5, *denotes p£ 0.05). (C) Representative karyotype analysis based on 20 G-banded
metaphase cells demonstrating normal chromosomes among CMSC-1-iPSCs (passage 5).
FIG. 4. Representative embryoid
body (EB) formation of CMSC-iPSCs.
(A) Morphology of EBs (day 14) from
CMSC-1-iPSC under brightfield mi-
croscopy (scale bar, 500mm). (B) RT-
PCR from EB RNA extracted between
21 and 28 days, demonstrating acti-
vation of ectodermal, mesodermal,
and endodermal genes. (C) Immuno-
fluorescence microscopy of EBs
merged with DAPI (in blue) showing
expression of AFP (endoderm),
a-SMA (mesoderm), and Nestin
(ectoderm, magnification, 100· ).
Color images available online at
www.liebertpub.com/tec
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markers, including AFP, SOX17, and FOXA2. Mesodermal
differentiation was confirmed by the presence of a-SMA, and
ectodermal differentiation was shown by positive Nestin and
TuJ1 staining.
Under neurogenic conditions, neurospheres attached
and formed neural rosettes typical of neuroepithelial cells
within 7 days of adherent culture (Fig. 5A, upper left).
These neural precursor cells were subsequently expanded
and analyzed at passage 8, showing widespread expres-
sion of various NSC markers, including Nestin, PSA-
NCAM, Musashi, and SOX3, by immunofluorescence
(Fig. 5A). Undifferentiated CMSC-iPSC controls did not
express these neurogenic markers (data not shown). Evi-
dence of early neuronal differentiation was also revealed
by TuJ1-positive cells with extended axonal processes
(Fig. 5A, lower left). RT-PCR analyses of NSCs differ-
entiated from CMSC-iPSCs (CMSC-iPSC-NSCs) showed
the downregulation of NANOG as well as subsequent
upregulation of neural progenitor transcription factors,
SOX1 (Fig. 5B) and PAX6. Nestin was constitutively
expressed at similar levels in both CMSCs and CMSC-
iPSCs. CMSC-iPSC-NSCs could be cryopreserved and
subsequently thawed with excellent survival and
re-expansion capabilities.
CMSC-iPSC-NSCs maintained in neurogenic media for up
to 2 months were capable of differentiation into more mature
neural phenotypes, including neurons and glial cells. Phase-
contrast microscopy showed characteristic morphological
changes, including extension of neuronal processes (Fig. 5C,
upper). Immunofluorescence staining revealed the expression
of TuJ1-positive (neuronal) and GFAP-positive (astrocyte)
cells without evidence of co-expression (Fig. 5C, lower).
Seven days after induction under cardiogenic conditions,
cells began to spontaneously contract (Supplementary Video
S1), consistent with mature cardiomyocyte differentiation.
Over time, the majority of cells continued to beat in a coor-
dinated rhythmic manner (mean frequency, 129.5– 3.6 beats
per minute at 50 days). Spontaneously contracting could be
maintained in culture for over 60 days (Fig. 6A). To confirm
directed differentiation into cardiomyocytes, immunofluo-
rescence staining showed strong expression within contract-
ing cells of MYH7, MF20, and a-actinin, consistent with
cardiac/skeletal myocytes (Fig. 6B). A more differentiated
cardiac phenotype was confirmed within CMSC-iPSC-CMs
FIG. 5. Directed differentiation of representative CMSC-iPSCs into the neural lineage. (A) Photomicrograph of typical
neural rosette formation under brightfield microscopy (upper left, magnification, 4· ), and morphology of representative
neural stem cells (NSCs) under phase microscopy (upper right, magnification, 100· ). Merged photomicrographs showing
positive immunofluorescence staining for several early neural markers (magnification, 40 · ), including PSA-NCAM (red,
middle left), Nestin (red, middle right), and TuJ1 (green, lower left). DAPI in blue, scale bar, 500mm. (B) Upon directed
differentiation into the neural lineage, there was loss of NANOG expression but gain in SOX1 expression by RT-PCR. (C)
Phase-contrast photomicrograph of more differentiated neural cells (magnification, 20· ) demonstrating characteristic
morphology (upper) that stain positively for TuJ1 (green) or GFAP (red) superimposed with blue DAPI (lower). Color
images available online at www.liebertpub.com/tec
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by robust expression of MLC2v, a protein specific to ven-
tricular cardiomyocytes (Fig. 6C). The absence of NANOG
as well as a-SMA and RUNX-1, both markers of early me-
sodermal differentiation, was confirmed by RT-PCR (data not
shown). Undifferentiated CMSC-iPSC controls did not ex-
press any cardiomyocyte markers (data not shown).
After 3 days under endodermal conditions, robust DE
differentiation was evidenced by double-positive immuno-
fluorescence staining of two transcriptional regulators,
FOXA1 and SOX17, in a significant proportion of cells
(Fig. 7A, lower right). RT-PCR analyses of these DE cells
derived from CMSC-iPSCs (CMSC-iPSC-DE) showed the
downregulation of NANOG with subsequent upregulation of
SOX17 (Fig. 7B). The lack of AFP, a marker seen in prim-
itive endodermal differentiation, was confirmed in CMSC-
iPSC-DE samples. Undifferentiated CMSC-iPSC controls did
not express any endodermal markers (data not shown).
Discussion
In this study, we successfully derived new human iPSC lines
from term fetal chorionic mesenchyme and demonstrated
FIG. 6. Directed differentiation of representative CMSC-iPSCs into cardiomyocytes (CMSC-iPSC-CMs). (A) Sponta-
neous contraction (beats per minute) of CMSC-1-iPSC-CMs maintained under cardiogenic conditions. Data presented as the
mean – SEM (n = 4–5 wells per time point). (B) Positive immunofluorescence staining of cardiomyocytes for myocyte
markers (red), including a-actinin and MF20 (upper, magnification, 40 · ) as well as MYH7 (lower, magnification, 20· ),
merged with DAPI. (C) Mature ventricular cardiomyocyte differentiation by phase (far left) and immunofluorescence
microscopy using an anti-MLC2v antibody (red) superimposed with DAPI (magnification, 20 · ). A muscle fiber is shown
by the white arrow. Color images available online at www.liebertpub.com/tec
FIG. 7. Directed differentiation of
representative CMSC-iPSCs into de-
finitive endoderm (DE). (A) Immuno-
fluorescence analysis of CMSC-1-
iPSC-DE demonstrating double-posi-
tive staining of two definitive endo-
derm transcriptional regulators,
FOXA2 (red) and SOX17 (green),
superimposed with DAPI (lower right,
magnification, 20 · ). Scale bar,
500 mm. (B) RT-PCR showing upre-
gulation in SOX17 with concomitant
downregulation in NANOG following
endodermal induction. The DE phe-
notype is further supported by the ab-
sence of AFP. Color images available
online at www.liebertpub.com/tec
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continuous expansion under feeder-free culture conditions, in-
cluding PMEDSAH, a defined synthetic polymer matrix. The
pluripotency of our CMSC-iPSCs, as revealed by controlled
in vitro differentiation of CMSCs into each of the three germ
layers, provides proof of concept of their potential in maternal–
fetal research and clinical applications. To our knowledge, only
one other study has successfully described iPSC reprogramming
of term human chorionic cells, but these cells were incompletely
characterized in vitro by pluripotency markers and functional
assays.20
Despite their heterogeneity and increased expression of
selected pluripotent markers, CMSCs are classified within the
family of placental MSCs based on criteria established by the
first international Workshop on Placenta Derived Stem
Cells.21 In most experimental models, MSCs and their related
cell types, including CD117-positive amniotic fluid stem
cells, have enhanced plasticity but appear to exert the bulk of
their actions in vivo as paracrinemediators via the secretion of
various factors that support the growth, survival, or charac-
teristics of other cells, rather than by direct terminal differ-
entiation into new tissue.22 Unlike true pluripotent stem cells,
extended in vitro culture of placental-based MSCs has gen-
erally been associated with cell senescence and reduced
plasticity beyond the mesodermal lineages.23
Although the reprogramming efficiency observed in our
study was relatively low, methods to enhance the iPSC
derivation of CMSCs and other fetal cell types remain on-
going. Regardless, the overall findings raise awareness re-
garding the potential benefits of banking placenta chorionic
cells for the future patient-specific therapeutic applications.
In most cases, human chorionic cells can be easily estab-
lished and expanded in primary culture from a small spec-
imen. In addition to providing a cellular substrate for iPSC
reprogramming, our work confirms that CMSCs are of fetal
origin and therefore would be available for gene and other
cell-based therapies later in life analogous to what is already
being done with umbilical cord blood banking for hemato-
poietic stem cell transplantation.
Although the use of fetal-derived somatic tissues as an al-
ternative cell source for iPSC reprogramming is not entirely
new,7,8,24–27 we believe that CMSCs are particularly novel,
unique, and practical cells for many perinatal tissue engi-
neering applications that would utilize pluripotent stem cell
technologies. Compared to many other possible cells that
could be obtained in this patient population, placenta-derived
MSCs can be easily expanded in vitro to generate a large
number of somatic cells, can be reliably reprogrammed with
only four transcription factors, have epigenetic memory clo-
ser to a pluripotent state, and have enhanced immunomodu-
latory properties even after iPSC induction that may be
advantageous for allogeneic applications.28 Experience in our
laboratory, among others, has shown that MSCs are less re-
liably isolated from umbilical cord blood samples.29,30
Moreover, cord blood hematopoietic cells are notoriously
difficult to expand in vitro, a property that has already limited
their therapeutic potential in clinical hematopoietic stem cell
transplantation. Four-factor iPSC reprogramming efficiency
rates as low as 0.0008% have been reported from mononu-
clear cells isolated from blood samples.31 Finally, blood-de-
rived somatic cells may also have increased epigenetic
memory biasing them toward hematopoietic differentiation
after cellular reprogramming.32
Ultimately, we anticipate that the many unique aspects of
human CMSCs, particularly their endogenous expression of
OCT4, Nestin, and other markers, suggest that these cells
may play a key role in unlocking some of the fundamental
questions with regard to epigenetic memory, conversion to
alternate cell phenotypes, and the development of transgene-
free cell-based therapeutic applications in infants and young
children with debilitating diseases. Differentiated cell types
derived from CMSC-iPSCs have enormous potential as
valuable in vitro platforms for disease modeling and testing
of pharmacological agents in children with congenital
anomalies. Pediatric disorders, including congenital heart
disease, pulmonary hypoplasia, and neurological develop-
ment disorders, are typically diagnosed prenatally and
therefore could be further investigated in these models once
the child is born. In addition, purified differentiated popu-
lations of cells derived from CMSC-iPSCs in vitro may
facilitate the development of autologous tissue engineering
and other cell-based therapies for some of the most difficult
perinatal disorders treated in neonatal intensive care units
worldwide.33 These diseases, all of which are manifested by
damage or loss of organ function, include neonatal hypoxic–
ischemic encephalopathy, cerebral palsy, spina bifida,
hypoplastic left heart syndrome, and fulminant hepatic
failure.34
Whereas the delivery of autologous CMSC-iPSCs might
be appealing for certain regenerative medicine applications,
allogeneic transplantation using cryopreserved cells derived
from human leukocyte antigen (HLA)-matched CMSC-
iPSCs stored within a biorepository represents another via-
ble alternative. An allogeneic approach might offer some
additional cost advantages, enabling the initiation of cell-
based treatments earlier in infancy. The ability to use
HLA-matched cells ‘‘off-the-shelf’’ without the need for
immunosuppression might also be feasible in this setting
given the known immunoregulatory properties of fetal-
derived mesenchymal cells.28,35
Conclusions
This study demonstrates the feasibility of term placental
chorion as a noninvasive alternative cell source for perinatal
iPSC derivation. Because human iPSCs derived from pla-
cental chorion have virtually identical properties to that of
human ESCs, they have enormous potential in fetal tissue
engineering and regenerative medicine research applications
and may provide additional insights regarding the repro-
gramming capabilities of extra-embryonic tissues as they
relate to developmental ontogeny.
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